Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study
Open Access
- 13 August 2020
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 9 (8) , 511
Abstract
Fosfomycin represents a relatively old antibiotic, but it is experiencing a comeback in recent years. According to some studies, the increasing therapeutic use of this drug led to a rapid increase in the levels of resistance in bacteria causing urinary tract infection. In the presented study, levels of resistance to fosfomycin in more than 3500 bacterial isolates before and after fosfomycin introduction into therapeutic use in the Czech Republic and the clinical efficacy of treatment in 300 patients using this drug were assessed. The results show that the resistance levels to fosfomycin in Escherichia coli isolates before and after the drug registration were not significantly different (3.4% and 4.4%, respectively). In some other Gram-negative rods, such as otherwise susceptible Enterobacter, resistance to fosfomycin increased significantly from 45.6% to 76.6%. Fosfomycin treatment of urinary tract infections showed an excellent seven-day clinical efficacy (79.7%). However, when used to treat recurrent or complicated urinary tract infections, fosfomycin treatment was associated with high levels of infection relapse, leading to relapse in a total of 20.4% of patients during the first two months. This indicates that fosfomycin exhibits good efficacy only for the treatment of uncomplicated urinary tract infectionsKeywords
Funding Information
- Ministerstvo Obrany České Republiky (Long term organization development plan)
- Ministerstvo Zdravotnictví Ceské Republiky (UHHK, 00179906)
This publication has 25 references indexed in Scilit:
- Fosfomycin: Resurgence of an old companionJournal of Infection and Chemotherapy, 2016
- Fosfomycin Susceptibility in Carbapenem-Resistant Enterobacteriaceae from GermanyJournal of Clinical Microbiology, 2014
- Susceptibility of Multiresistant Gram-Negative Bacteria to Fosfomycin and Performance of Different Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2014
- Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre studyBMJ Open, 2013
- Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in TurkeyInternational Journal of Infectious Diseases, 2013
- Determination of Extended-Spectrum β-Lactamases and AmpC Production in Uropathogenic Isolates of Escherichia coli and Susceptibility to FosfomycinJournal of Laboratory Physicians, 2013
- Experience with Fosfomycin for Treatment of Urinary Tract Infections Due to Multidrug-Resistant OrganismsAntimicrobial Agents and Chemotherapy, 2012
- Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in TaiwanJournal of Microbiology, Immunology and Infection, 2011
- Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic reviewThe Lancet Infectious Diseases, 2010
- Susceptibility of Urinary Tract Bacteria to FosfomycinAntimicrobial Agents and Chemotherapy, 2009